PPARGC1A and non-small cell lung carcinoma: In a recent report, cisplatin resistance involves metabolic reprogramming through ROS and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) in non-small cell lung cancer [15], suggesting that metformin promotes the cisplatin sensitivity of gastric cancer by elevating oxidative stress and inhibiting metabolic reprogramming.